TNFRSF17 and Miyoshi myopathy: The past decade has witnessed the booming field of CAR-T therapy and the remarkable clinical activity of anti-BCMA therapy in MM, and two CAR-T products against BCMA were thereby approved by the US Food and Drug Administration (FDA) for RRMM, with a great deal of CAR-T products under development in pre-clinical and clinical trials.